IBDEI0KH ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9522,2)
 ;;=^5002448
 ;;^UTILITY(U,$J,358.3,9523,0)
 ;;=H53.71^^41^480^7
 ;;^UTILITY(U,$J,358.3,9523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9523,1,3,0)
 ;;=3^Glare Sensitivity
 ;;^UTILITY(U,$J,358.3,9523,1,4,0)
 ;;=4^H53.71
 ;;^UTILITY(U,$J,358.3,9523,2)
 ;;=^5006354
 ;;^UTILITY(U,$J,358.3,9524,0)
 ;;=H53.72^^41^480^9
 ;;^UTILITY(U,$J,358.3,9524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9524,1,3,0)
 ;;=3^Impaired Contrast Sensitivity
 ;;^UTILITY(U,$J,358.3,9524,1,4,0)
 ;;=4^H53.72
 ;;^UTILITY(U,$J,358.3,9524,2)
 ;;=^5006355
 ;;^UTILITY(U,$J,358.3,9525,0)
 ;;=H57.13^^41^480^14
 ;;^UTILITY(U,$J,358.3,9525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9525,1,3,0)
 ;;=3^Ocular Pain,Bilateral
 ;;^UTILITY(U,$J,358.3,9525,1,4,0)
 ;;=4^H57.13
 ;;^UTILITY(U,$J,358.3,9525,2)
 ;;=^5006384
 ;;^UTILITY(U,$J,358.3,9526,0)
 ;;=H57.11^^41^480^16
 ;;^UTILITY(U,$J,358.3,9526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9526,1,3,0)
 ;;=3^Ocular Pain,Right Eye
 ;;^UTILITY(U,$J,358.3,9526,1,4,0)
 ;;=4^H57.11
 ;;^UTILITY(U,$J,358.3,9526,2)
 ;;=^5006382
 ;;^UTILITY(U,$J,358.3,9527,0)
 ;;=H57.12^^41^480^15
 ;;^UTILITY(U,$J,358.3,9527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9527,1,3,0)
 ;;=3^Ocular Pain,Left Eye
 ;;^UTILITY(U,$J,358.3,9527,1,4,0)
 ;;=4^H57.12
 ;;^UTILITY(U,$J,358.3,9527,2)
 ;;=^5006383
 ;;^UTILITY(U,$J,358.3,9528,0)
 ;;=I10.^^41^480^8
 ;;^UTILITY(U,$J,358.3,9528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9528,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,9528,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,9528,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,9529,0)
 ;;=L71.9^^41^480^19
 ;;^UTILITY(U,$J,358.3,9529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9529,1,3,0)
 ;;=3^Rosacea,Unspec
 ;;^UTILITY(U,$J,358.3,9529,1,4,0)
 ;;=4^L71.9
 ;;^UTILITY(U,$J,358.3,9529,2)
 ;;=^5009276
 ;;^UTILITY(U,$J,358.3,9530,0)
 ;;=L71.8^^41^480^18
 ;;^UTILITY(U,$J,358.3,9530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9530,1,3,0)
 ;;=3^Rosacea NEC
 ;;^UTILITY(U,$J,358.3,9530,1,4,0)
 ;;=4^L71.8
 ;;^UTILITY(U,$J,358.3,9530,2)
 ;;=^5009275
 ;;^UTILITY(U,$J,358.3,9531,0)
 ;;=L71.1^^41^480^17
 ;;^UTILITY(U,$J,358.3,9531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9531,1,3,0)
 ;;=3^Rhinophyma
 ;;^UTILITY(U,$J,358.3,9531,1,4,0)
 ;;=4^L71.1
 ;;^UTILITY(U,$J,358.3,9531,2)
 ;;=^106083
 ;;^UTILITY(U,$J,358.3,9532,0)
 ;;=S05.31XA^^41^480^13
 ;;^UTILITY(U,$J,358.3,9532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9532,1,3,0)
 ;;=3^Ocular Laceration Right Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,9532,1,4,0)
 ;;=4^S05.31XA
 ;;^UTILITY(U,$J,358.3,9532,2)
 ;;=^5020606
 ;;^UTILITY(U,$J,358.3,9533,0)
 ;;=S05.32XA^^41^480^12
 ;;^UTILITY(U,$J,358.3,9533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9533,1,3,0)
 ;;=3^Ocular Laceration Left Eye w/o Prolapse/Loss of Intraoc Tissue,Init Encntr
 ;;^UTILITY(U,$J,358.3,9533,1,4,0)
 ;;=4^S05.32XA
 ;;^UTILITY(U,$J,358.3,9533,2)
 ;;=^5020609
 ;;^UTILITY(U,$J,358.3,9534,0)
 ;;=Z21.^^41^480^2
 ;;^UTILITY(U,$J,358.3,9534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9534,1,3,0)
 ;;=3^Asymptomatic HIV Infection Status
 ;;^UTILITY(U,$J,358.3,9534,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,9534,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,9535,0)
 ;;=Z83.511^^41^480^6
 ;;^UTILITY(U,$J,358.3,9535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9535,1,3,0)
 ;;=3^Family Hx of Glaucoma
 ;;^UTILITY(U,$J,358.3,9535,1,4,0)
 ;;=4^Z83.511
 ;;^UTILITY(U,$J,358.3,9535,2)
 ;;=^5063382
 ;;^UTILITY(U,$J,358.3,9536,0)
 ;;=Z83.518^^41^480^5
 ;;^UTILITY(U,$J,358.3,9536,1,0)
 ;;=^358.31IA^4^2
